
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc. has demonstrated strong revenue growth, with surgical soft tissue repair product sales increasing by 24% year-over-year, reaching $23.4 million, alongside a positive trajectory for other product lines such as bone fusion products. The company is poised for continued growth with an anticipated revenue increase of 13-17% for 2026, following a 3-5% growth in 2025, and has recently achieved profitability in its continuing operations as of the third quarter of 2025. Additionally, the securing of a contract with Vizient, the largest group purchasing organization in the U.S., is expected to further enhance Sanara's market access and bolster revenue streams through expanded sales of its products at pre-negotiated terms.
Bears say
Sanara MedTech Inc. reported net revenue of $26.3 million, reflecting a year-over-year growth of 21.5%, which was slightly below projected figures, raising concerns about revenue generation capabilities. The company's outlook is hindered by several risks, including the potential for lower-than-expected revenue growth, challenges in acquiring new customers, and difficulties in launching new products and services. Furthermore, a significant reduction in the EV/Revenue multiple from 4.3x to 3.0x suggests a reassessment of the company’s market valuation following the exclusion of telehealth from its business model.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares